mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/P13K/Akt pathway

Details for Australian Patent Application No. 2009320137 (hide)

Owner Signal Pharmaceuticals, LLC

Inventors Elsner, Jan; Harris, Roy L.; Lee, Branden; Mortensen, Deborah; Packard, Garrick; Papa, Patrick; PerrinNinkovic, Sophie; Riggs, Jennifer; Sankar, Sabita; Sapienza, John; Shevlin, Graziella; Tehrani, Lida; Xu, Weiming; Zhao, Jingjing; Parnes, Jason; Madakamutil Loui; Fultz Kimberly; Narla, Rama K.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2009320137

PCT Pub. Number WO2010/062571

Priority 61/108,627 27.10.08 US

Filing date 27 October 2009

Wipo publication date 3 June 2010

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/4985 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

26 May 2011 PCT application entered the National Phase

  PCT publication WO2010/062571 Priority application(s): WO2010/062571

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009320139-Synthetic mimetics of host defense and uses thereof

2009320133-Method and system for optimizing a cooling model of a data center